Trusted Resources: Education
Scientific literature and patient education texts
Guidelines for High Dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis: EHA-ISA Working Group Guidelines
source: Amyloid: The Official Journal of the International Society of Amyloidosis
year: 2021
authors: Vaishali Sanchorawala, Mario Boccadoro, Morie Gertz, Ute Hegenbart, Efstathios Kastritis, Heather Landau, Peter Mollee, Ashutosh Wechalekar, Giovanni Palladini
summary/abstract:AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. High dose intravenous melphalan and autologous stem cell transplantation was developed for the treatment of AL amyloidosis in the early 1990s and was prompted by its success in multiple myeloma. This application has evolved significantly over the past three decades. These guidelines provide a comprehensive assessment of eligibility criteria, stem cell collection and mobilisation strategies and regimens, risk-adapted melphalan dosing, role for induction and consolidation therapies, specific supportive care management, long-term outcome with respect to survival, haematologic response and relapse and organ responses following stem cell transplantation. These guidelines are developed by the experts in the field on behalf of the stem cell transplant working group of the International Society of Amyloidosis (ISA) and European Haematology Association (EHA).
organization: Boston University School of Medicine and Boston Medical Center, USA; University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Italy; Mayo Clinic, Rochester, USA; Heidelberg University Hospital, Germany; National and Kapodistrian University of Athens, Alexandra General Hospital, Greece; Memorial Sloan Kettering Cancer Center, USA; Princess Alexandra Hospital and University of Queensland, Australia; University College London, UK; Amyloidosis Research and Treatment Center, University of Pavia, ItalyDOI: 10.1080/13506129.2021.2002841
read more
Related Content
-
Lentzsch: Bispecific Antibodies and Beyond in AL Amyloidosis – ASG AL Webinar 2.24.24 – 2/8https://www.youtube.com/watch?v=lzrMgtOC...
-
Light Chain (AL) Amyloidosis: Treatment in 2020 and Beyond – Webinarhttps://www.youtube.com/watch?v=GC4AiYef...
-
Amyloidosis, A Tricky Diagnosis, Can Be Traced to Vietnam and Exposure to Agent OrangeMarch being Amyloidosis Awareness Month,...
-
AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and TherapyThe amyloidoses are a group of protein-f...
-
Cardiac Amyloidosis Part 1: Understanding Types and Riskshttps://www.youtube.com/watch?v=bE68vvDt...
-
FDA OKs Inotersen (Tegsedi) for Hereditary ATTR With PolyneuropathyThe US Food and Drug Administration (FDA...
-
The Effect and Safety of Bortezomib in the Treatment of AL Amyloidosis: A Systematic Review and Meta-AnalysisBortezomib began to be used in the treat...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.